drugset / Trial / NCT03510663
Phase I Study of OPC-61815
RandomizedCrossoverTriple-blindTreatment
Summary
To investigate the effects of intravenous administration of OPC-61815 at 16 and 32 mg on QT/QTc interval in healthy male subjects
Timeline
- Start
- 2018-05-08
- Primary completion
- 2018-07-05
- Completion
- 2018-07-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Moxifloxacin | Small molecule | 400 mg | — |
| Subject | OPC-61815 | Unknown | 16 mg | Intravenous |
| Subject | OPC-61815 | Unknown | 32 mg | Intravenous |